The test detects 21 relevant mutations in the KRAS oncogene including mutations in exons 2, 3, and 4.
The Belgian MDx firm's sights are set on assays for cancer, infectious disease, and sepsis, as well as new iterations of its flagship Idylla platform.
The companies' first offering is expected to be a multiplex respiratory disease panel.
Three new assays were presented in posters at April's Clinical Virology Symposium.
The company issued more than 8.6 million shares at €11.50 per share in its IPO. Its shares list on Euronext Brussels under ticker symbol "BCART."
The partners will collaborate on a multiplex, real-time PCR-based assay for use with Biocartis' pre-enrichment platform, currently under development.
Biocartis will initially test the device against synthetic virus samples and subsequently run trials in West Africa.
Officials from Exact Sciences, Cepheid, Bio-Rad, Biocartis, and NanoString provided strategic updates at the conference.
After receiving ISO certification and publishing studies on its technology in 2014, the Australian MDx firm is targeting a launch of its meningitis test in 2015.
NEW YORK (GenomeWeb) – Recently launched Biocartis-Pronota joint venture MyCartis is taking aim at the multi-omics space, looking to combine genomic, transcriptomic, and proteomic analyses for the development of research and clinical products.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.